IJCRR - vol 05 issue 13, July, 2013
EVALUATION OF SERUM LEVELS OF REDUCED GLUTATHIONE, GLUTATHIONE-S-TRANSFERASE AND NITRIC OXIDE IN BREAST CANCER PATIENTS UNDERGOING ADJUVANT CHEMOTHERAPY
Author: Charushila Y. Kadam, Subodhini A. Abhang
Background: Alteration in oxidative and nitrosative stress as well as antioxidant status is known to occur in carcinogenesis and during treatment of cancer with chemotherapeutic drugs. Objective: The objective of this study was to evaluate the serum levels of reduced glutathione (GSH) glutathione-s-transferase (GST) and nitric oxide (NO•) in post-operative stage II breast cancer patients undergoing adjuvant chemotherapeutic treatment. Material and Methods: Clinically and histopathologically proven 30 stage II breast cancer patients were selected for the present study. Blood was collected after mastectomy before start of 1st adjuvant chemotherapy cycle and 3 weeks after receiving 1st cycle of chemotherapy. 30 healthy controls were selected for comparison. Serum GSH, GST and NO• levels were estimated by spectrophotometric methods. Results: The serum level of reduced glutathione was significantly lower (P<0.0004) whereas serum levels of GST and NO• were significantly higher (P<0.0001) in post-operative stage II breast cancer patients before chemotherapy as compared to healthy controls. After 3 weeks of receiving 1st adjuvant chemotherapy cycle, significant decrease in the serum levels of GSH, GST and NO• was observed (P<0.0001) as compared to levels before chemotherapy in these patients. Significant positive correlation was found between GSH and NO• (r=+0.96) and GSH and GST (r= +0.91) after chemotherapy. Conclusion: The findings of the study suggests that administration of chemotherapeutic drugs in adjuvant setting in breast cancer patients causes increase in oxidative stress as indicated by decreased levels of antioxidant glutathione. The observed decrease in levels of GST and NO• might be associated with decrease in levels of GSH in these patients after chemotherapy.
Keywords: Antioxidants, Oxidative stress, FEC, S-nitrosoglutathione.
Charushila Y. Kadam, Subodhini A. Abhang. EVALUATION OF SERUM LEVELS OF REDUCED GLUTATHIONE, GLUTATHIONE-S-TRANSFERASE AND NITRIC OXIDE IN BREAST CANCER PATIENTS UNDERGOING ADJUVANT CHEMOTHERAPY International Journal of Current Research and Review. vol 05 issue 13, July, 51-57
1. Rajneesh CP, Manimaran A, Sasikala KR, Adaikappan P. Lipid peroxidation and antioxidant status in patients with breast cancer. Singapore Med J 2008; 49(8):640-3.
2. Gonec A, Erten D, Aslan S, Akinci M, Simsek B, Torun M. Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease. Cell Biol Int 2006; 30:376-80.
3. Prabasheela B, Singh AK, Fathima A, Pragulbh K, Deka NJ, Kumar R. Association between antioxidant enzymes and breast cancer. Recent Res Sci Technol 2011;3(11): 93-5.
4. Simone CB, Simone NL, Simone V, Simone CB. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill survival, Part 1. Altern Ther Health Med 2007; 13(1):22-8.
5. Horn SL, Fentiman IS. The role of nonsteroidal anti-inflammatory drugs in the chemoprevention of breast cancer. Pharmaceuticals 2010;3:1550-60.
6. Toyokuni S, Okamato K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS Letters 1995; 358:1-3.
7. Panis C, Herrere AC, Victorino VJ, Campos FC, Freitas LF, De Rossi T, et al. Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy. Breast Cancer Res Treat 2012;133:89-97.
8. Ewadh MJ, Kadhum NH, Al Hamdani KJ, Alawad AS. Relationship between antioxidants glutathione and total α-L-fucose as tumor markers in breast cancer patients. Medical Journal of Babylon 2009;6(1):164- 75.
9. Sivakumar S, Devaraj N. Enzymatic and nonenzymatic antioxidant status of breast cancer patients in Tamilnadu. IJPBS 2011;2(4):B46- 53.
10. Davis W, Ronai Z, Tew KD. Cellular thiols and reactive oxygen species in drug-induced apoptosis. J Pharmacol Exp Ther 2001;296:1- 6.
11. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr 2004;134:489- 92. `
12. Harbrecht BG, Silvio MD, Chough V, Kim YM, Simmons RL, Billiar TR. Glutathione regulates nitric oxide synthase in cultured hepatocytes. Ann Surg 1997; 225(1):76-87.
13. Vos TA, Goor HV, Tuyt L, De JagerKrikken, A,Leuvenink R, Kuipers F, et al. Expression of inducible nitric oxide synthase in endotoxemic rat hepatocytes is dependent on the cellular glutathione status. Hepatology 1999;29:421-26.
14. Bakan E, Taysi S, Polat MF, Dalga S, Umudem Z, Bakan N, et al. Nitric oxide levels and lipid peroxidation in plasma of patients with gastric cancer. Jpn J Clin Oncol 2002;32(5):162-6.
15. Mahdy EM, Shousha WG, Ahmed HH, Metwally FM, Ramadan SS. Significance of serum HGF, Bcl-2 and Nitric oxide in primary breast cancer. Nature and Science 2011;9(5):34-41.
16. Coskun U, Gunel N, Sancak B, Onuk E, Bayram M, Cihan A. Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric activities in breast carcinoma patients. Clin Exp Immunol 2004;137:546- 51.
17. Alagol H, Erdem E, Sancak B, Turkmen G, Camlibel M, Bugdayci G. Nitric oxide biosynthesis and malondialdehyde levels in advanced breast cancer. Aust N Z J Surg 1999;69 :647-50.
18. Ewadh MJ, Kadhum NH, Al Hamdani KJ, Alawad AS. The relation between antioxidants Glutathione, Glutathione-stransferase as tumor markers in breast cancer patients. Medical Journal of Babylon 2009;6(1):36-44.
19. Konukoglu D, Turhan MS, Celik V, Turna H. Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide and urokinase-type plasminogen activator in breast cancer patients. Indian J Med Res 2007;125:747-51.
20. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione-s-transferase activities in rat lung and liver. Biochim Biophys Acta 1979;582:67-78.
21. Prabhu K, Bhat GP. Serum total glutathiones-transferase levels in oral cancer. J Can Res Ther 2007;3:167-8.
22. Cortas NK, Wakid NB. Determination of inorganic nitrate in serum and urine by a kinetic cadmium reduction method. Clin Chem 1990;36:1440-3.
23. Peters WHM, Roelofs HMJ, Putten WLJV, Jansen JBMJ. Response to adjuvant chemotherapy in primary breast cancer: no correlation with expression of glutathione-stransferases. Br J Cancer 1993;68:86-92.
24. Conklin KA. Cancer chemotherapy and antioxidants. J Nutr 2004;134(11):3201-4S.
25. Chakraborty P, Ugir HSK, Murmu N, Das JK, Pal S, Bhattacharya S. Modulation of Cyclophosphamide –induced cellular toxicity by diphenylmethyl selenocyanate in vivo, an enzymatic study, J Cancer Molecules 2009;4(6):183-9.
26. Czeczot H, Scibior D, Skrzycki M, Podsiad M, Porembska Z. Glutathione level and activity of GSH dependent enzymes in gastric carcinoma patients-a preliminary report. Gastroenterol Pol 2005;12(2):107-11.
27. Mishra S, Sharma DC, Sharma P. Studies of biochemical parameters in breast cancer with and without metastasis. Indian J Clin Biochem 2004;19(1):71-5.
28. Kasapovic J, Pejic S, Stojiljkovic V, Todorovic A, Radosevic-Jelic L, Saicic ZS, et al. Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages after chemotherapy with 5-fluorouracil, doxorubicin and Cyclophosphamide. Clin Biochem 2010;43(16-17):1287-1293.
29. Prabasheela B, Baskaran S, Alteration of glutathione dependent enzymes in pre and post-operative breast carcinoma, JBMAS. 1- 7.
30. Severini G. Glutathione-s-transferase activity in patients with cancer of the digestive tract. J Cancer Res Clin Oncol 1993;120(1-2):112-4.
31. Gunel N, Coskun U, Sancak B, Hasdemir O, et al, Prognostic value of serum IL-18, and nitric oxide activity in breast cancer patients at operable stage. Am J Clin Oncol 2003; 26(4):416-21.